NRBO Profile
NeuroBo Pharmaceuticals, Inc., based in Boston, Massachusetts, is a clinical-stage biotechnology company dedicated to developing and commercializing innovative, multimodal therapies targeting a range of viral, neuropathic, and neurodegenerative diseases. The company focuses on creating disease-modifying treatments that address unmet medical needs across several therapeutic areas, leveraging its expertise in advanced drug development and formulation.
One of NeuroBo's leading candidates is ANA001, a proprietary oral formulation of niclosamide designed for the treatment of moderate COVID-19. This novel approach aims to leverage niclosamide's antiviral properties to address the ongoing challenges of COVID-19. The company is also advancing NB-01, a targeted therapy for painful diabetic neuropathy, which seeks to alleviate the debilitating pain associated with this common diabetic complication.
NeuroBo is developing NB-02, a therapeutic agent aimed at treating cognitive impairment and modifying the progression of neurodegenerative diseases linked to tau protein dysfunction. This investigational treatment is designed to address the underlying pathology of disorders such as Alzheimer's disease. Additionally, NeuroBo is exploring the use of Gemcabene, an investigational drug with potential applications for various conditions, including COVID-19 in combination with ANA001.
Founded with a mission to tackle complex and challenging diseases, NeuroBo Pharmaceuticals is at the forefront of biopharmaceutical innovation. The company's commitment to advancing its pipeline through rigorous clinical development reflects its dedication to improving patient outcomes across a spectrum of conditions. As it continues to progress its therapies through clinical trials, NeuroBo remains focused on delivering transformative treatments for patients with serious and unmet medical needs.
|
